Table 2.

Prognostic Models for HDC for NSGCT

Model		Factor		Points	2-year EFS
Beyer	Variables	Progressive disease before HDC		1
		Mediastinal primary tumor		1
		Cisplatin-refractory disease (relapse within 4 weeks of completion of first-line chemotherapy)		1
		Absolute cisplatin-refractory disease (PD as best response to prior therapy)		2
		B-HCG > 1,000 IU/L before HDC		2
	Stratification	Low risk		0	51%
		Intermediate risk		1-2	27%
		High risk		>2	5%
Einhorn	Variables	HDC at third-line or subsequent line of treatment		3
		Refractory disease before HDC (relapse within 4 weeks of completion of first line chemotherapy)		2
		High-risk IGCCCG stage		2
	Stratification	Low risk		0	80%
		Intermediate risk		2-3	60%
		High risk		>3	40%
International Prognostic Factors Study Group	Variables	Histology	Seminoma	−1
			Nonseminoma	0
		Primary tumor site	Mediastinal	3
			Retroperitoneal	1
			Gonadal	0
		Response to first-line chemotherapy	CR/PRm−	0
			PRm+/SD	1
			PD	2
		Progression-free interval following first-line chemotherapy	>3 months	0
			≤3 months	1
		AFP at salvage	Normal	0
			≤1,000	1
			>1,000	2
		B-HCG at salvage	≤1,000	0
			>1,000	1
		Liver/brain/bone metastases	No	0
			Yes	1
	Stratification	Very low risk (seminoma + low risk)		−1	92%
		Low risk		0	64%
		Intermediate risk		1-2	53%
		High risk		3-4	33%
		Very high risk		>4	22%